EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Plasma Viral Load of 200 Copies/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon

Collins Ambe Chenwi iD, Rachel Audrey Nayang Mundo, Alex Durand Nka, Ezechiel Ngoufack Jagni Semengue, Grâce Angong Beloumou, Aude Christelle Ka'e, Willy Leroi Togna Pabo, Désiré Takou, Aissatou Abba, Sandrine Claire Djupsa, Evariste Molimbou, Naomi-Karell Etame und 19 weitere

Journal of the International Association of Providers of AIDS Care (JIAPAC) · 2024

DOI: 10.1177/23259582241306484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the International Association of Providers of AIDS Care (JIAPAC), 2024. Verfasst von Collins Ambe Chenwi und 30 weiteren Autor:innen. Beteiligte Einrichtung: Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon. Hauptthemen laut MEDLINE: HIV Infections, Viral Load, HIV-1, Drug Resistance, Viral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chantal Biya International Reference Center for Research on HIV and AIDS prevention and management.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In low-and-middle-income-countries (LMIC), viral suppression is defined as plasma viral load (PVL) below 1000 copies/mL (low-level viremia [LLV]) and threshold for HIV drug resistance (HIVDR) testing. However, there is evidence that drug resistance mutations (DRMs) may emerge at LLV, thus compromising antiretroviral treatment (ART) response. We evaluated sequencing success rates (SSR) at LLV, described HIVDR profiles and adequacy with potential efficacy of tenofovir-lamivudine-dolutegravir (TLD).

Methods

A cross-sectional study was conducted among individuals with LLV at the Chantal BIYA International Reference Centre, Yaoundé, Cameroon from January 2020 through August 2021. HIV-1 sequencing was performed on protease/reverse-transcriptase, and sequences analysed using Stanford HIVdbv9.5. SSR and HIVDR rates were assessed according to viral-load ranges, with P < .05 considered statistically significant.

Results

In total, 131 individuals were enrolled (median [IQR] age = 41 [30−49] years; 67.9% female; 54.7% at WHO clinical-stage I/II; median ART-duration 7 [4−11] years; median CD4-count 221 [103−402] cells/mm 3 and median PVL 222 [96−436] copies/mL). Overall, SSR at LLV was 34.4% (45/131) and increased significantly with decreasing-age ( P = .002) and increasing-PVL ( P = .017). SSR were doubled at PVL≥150 copies/mL (21.8% at [40−150] vs. 43.3% at [150−1000]; OR = 2.8, P = .01). Of the 45 sequences obtained, 75.6% were recombinant strains (CRF02_AG, CRF09_cpx, CRF11_cpx) and 24.4% pure-subtypes (A1, D, F2, G). Overall, HIVDR prevalence at LLV was 82.2% (37/45), with 74.6% and 15.6% resistance to reverse-transcriptase inhibitors (RTIs) and ritonavir-boosted protease inhibitors (PI/r) respectively. Interestingly, HIVDR rates were similar at PVLs [50−200] versus [200−1000] copies/mL ( P = .69). The most frequent DRMs were M184 V (73.3%) and K103N (40.0%) for RTIs and M46I (6.7%) for PIs/r. Overall 55.6% (25/45) of individuals were on suboptimal ART (needing ART-optimisation), with 48.9% (22/45) having suboptimal TLD predictive efficacy. Optimisation need was higher in first-line (81.8%, P = .03), but similar across viral clades and PVL-ranges ( P = .6).

Conclusion

In this LMIC context, sequencing for HIVDR is feasible at LLV even with broad HIV-1 diversity, with significantly higher SSR above 150 copies/mL and/or in paediatrics. About 80% of individuals with LLV harbour HIVDR strains, with half of them needing ART optimisations to limit HIVDR emergence and prevent treatment failure. Our findings underscore the clinical benefits of HIVDR during persisting LLV and the need to reconsider the threshold for viral suppression around 200copies/mL in LMICs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsViral LoadHIV-1Drug Resistance, ViralAnti-HIV AgentsHumansCameroonFemaleCross-Sectional StudiesAdultMaleMiddle AgedDeveloping Countries

Stichwörter der Autor:innen

CameroonHIVantiretroviral resistancegenotypelow-level viremia

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.
  • University of Rome Tor Vergata, Rome, Italy.
  • Protestant University of Central Africa, Yaounde, Cameroon.
  • Evangelic University of Cameroon, Bandjoun, Cameroon.
  • Faculty of Health Sciences, University of Buea, Buea, Cameroon.
  • Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon.

ORCID-Profile: Collins Ambe Chenwi

Förderung

  • Chantal Biya International Reference Center for Research on HIV and AIDS prevention and management

Zitieren

APA

Chenwi, C. A., Nayang Mundo, R. A., Nka, A. D., Semengue, E. N. J., Beloumou, G. A., Ka'e, A. C., Togna Pabo, W. L., Takou, D., Abba, A., Djupsa, S. C., Molimbou, E., Etame, N. K., Kengni Ngueko, A. M., Same, D. K., Bouba Pamen, J. N., Abah Abah, A. S., Billong, S. C., Ajeh Awoh, R., Halle-Ekane, G. E., …, & Fokam, J. (2024). Plasma Viral Load of 200 Copies/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon. Journal of the International Association of Providers of AIDS Care (JIAPAC). https://doi.org/10.1177/23259582241306484

Vancouver

Chenwi CA, Nayang Mundo RA, Nka AD, Semengue ENJ, Beloumou GA, Ka'e AC, et al. Plasma Viral Load of 200 Copies/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2024. doi:10.1177/23259582241306484

BibTeX
@article{Chenwi2024,
  author = {Chenwi, Collins Ambe and Nayang Mundo, Rachel Audrey and Nka, Alex Durand and Semengue, Ezechiel Ngoufack Jagni and Beloumou, Grâce Angong and Ka'e, Aude Christelle and Togna Pabo, Willy Leroi and Takou, Désiré and Abba, Aissatou and Djupsa, Sandrine Claire and Molimbou, Evariste and Etame, Naomi-Karell and Kengni Ngueko, Aurelie Minelle and Same, David Kob and Bouba Pamen, Jolle Nounouce and Abah Abah, Aristide Stephane and Billong, Serge Clotaire and Ajeh Awoh, Rogers and Halle-Ekane, Gregory Edie and Cappelli, Giulia and Njom-Nlend, Anne-Esther and Zk Bissek, Anne-Cecile and Temfack, Elvis and Santoro, Maria Mercedes and Ceccherini-Silberstein, Francesca and Colizzi, Vittorio and Kaseya, Jean and Ndembi, Nicaise and Ndjolo, Alexis and Perno, Carlo Federico and Fokam, Joseph},
  title = {Plasma Viral Load of 200 Copies/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon},
  journal = {Journal of the International Association of Providers of AIDS Care (JIAPAC)},
  year = {2024},
  doi = {10.1177/23259582241306484}
}
Kostenlos starten →